Sanofi

October 24, 2018

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
October 16, 2017

Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery

[vc_row][vc_column][vc_column_text] German pharmaceutical company Evotec has expanded its partnership with Scottish artificial intelligence drug design pioneers Exscientia, investing a further €15m in exchange for a minority […]
August 23, 2016

Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation […]